Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial
Abstract Background Atrial infarction reportedly occurs in 0.7% to 52% of ST-elevation myocardial infarctions (STEMIs), up to two thirds of whom develop atrial fibrillation and flutter (AF). Prospective validation of electrocardiographic atrial infarction patterns is lacking. Hence, in STEMI patient...
Gespeichert in:
| Veröffentlicht in: | Journal of electrocardiology 2010-07, Vol.43 (4), p.351-358 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 358 |
|---|---|
| container_issue | 4 |
| container_start_page | 351 |
| container_title | Journal of electrocardiology |
| container_volume | 43 |
| creator | van Diepen, Sean, MD Siha, Hany, MD Fu, Yuling, MD Westerhout, Cynthia M., PhD Lopes, Renato D., MD Granger, Christopher B., MD Armstrong, Paul W., MD |
| description | Abstract Background Atrial infarction reportedly occurs in 0.7% to 52% of ST-elevation myocardial infarctions (STEMIs), up to two thirds of whom develop atrial fibrillation and flutter (AF). Prospective validation of electrocardiographic atrial infarction patterns is lacking. Hence, in STEMI patients treated with primary percutaneous coronary intervention, we examined whether baseline atrial electrocardiographic changes or atrial infarction patterns predicted new AF or mortality. Methods Within the Assessment of Pexelizumab in Acute Myocardial Infarction trial, a nested case-control study was conducted. Patients with new AF were matched 1:1 with controls, and baseline atrial electrocardiographic variables were examined. Results Abnormal P wave morphology (Liu minor criterion for atrial infarction) was significantly associated with new AF (adjusted odds ratio, 1.68; 1.03-2.73). This was also independently associated with 90-day mortality in the overall case-control cohort (adjusted hazard rate, 1.90; 1.04-3.46) and among patient with new-onset AF (adjusted hazard rate, 2.43; 1.22-4.84). Conclusions Abnormal P wave morphology significantly predicted new AF and 90-day mortality in STEMI patients. |
| doi_str_mv | 10.1016/j.jelectrocard.2010.04.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733984687</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0022073610001858</els_id><sourcerecordid>733984687</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-29dd8f40a37307416176777b940136480bd5b8cbc927b0722e5fe149d79c8d7b3</originalsourceid><addsrcrecordid>eNqNks9u1DAQxiMEokvhFZDFhVOWceyNEw6gVcuflYpA6nK2HGfS9ZLYW9spLE_Lo-AlLVtxwpdI9je_mcz3ZdkLCnMKtHy1nW-xRx2908q38wLSA_A5AH2QzeiCFXnFGTzMZgBFkYNg5Un2JIQtANSFKB5nJwXwdMp6lv06d6RRAXtjkajojerJPbhxV17tNkYTZVtibKe8jsZZslMxoreB7Dy2Rkdi8XvubMB4R-lM403fqz9y1SU1uVzniX0zXQ37qUOSHrlvycoGc7WJgXTeDSRukCxDwBAGtJG4jnzBH2nYn-OgmlRHlnqMSD4dWavjjOvDHE-zR53qAz67_Z5mX9-_W599zC8-f1idLS9yzRmPeVG3bdVxUEwwEJyWVJRCiKbmQFnJK2jaRVPpRqcNNiCKAhcdUl63otZVKxp2mr2cuDvvrkcMUQ4maEwLsOjGIAVjdcXLSiTl60mpvQvBYyd33gzK7yUFeTBYbuV9g-XBYAlcJoNT8fPbNmMzYPu39M7RJDifBJh-9sagl0EbtDq55BNSts78X583_2B0iojRqv-GewxbN3qb1impDIUEeXmI2iFpNIWMVouK_QbSFdkZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733984687</pqid></control><display><type>article</type><title>Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial</title><source>MEDLINE</source><source>ScienceDirect</source><creator>van Diepen, Sean, MD ; Siha, Hany, MD ; Fu, Yuling, MD ; Westerhout, Cynthia M., PhD ; Lopes, Renato D., MD ; Granger, Christopher B., MD ; Armstrong, Paul W., MD</creator><creatorcontrib>van Diepen, Sean, MD ; Siha, Hany, MD ; Fu, Yuling, MD ; Westerhout, Cynthia M., PhD ; Lopes, Renato D., MD ; Granger, Christopher B., MD ; Armstrong, Paul W., MD ; for the APEX AMI Investigators ; APEX AMI Investigators</creatorcontrib><description>Abstract Background Atrial infarction reportedly occurs in 0.7% to 52% of ST-elevation myocardial infarctions (STEMIs), up to two thirds of whom develop atrial fibrillation and flutter (AF). Prospective validation of electrocardiographic atrial infarction patterns is lacking. Hence, in STEMI patients treated with primary percutaneous coronary intervention, we examined whether baseline atrial electrocardiographic changes or atrial infarction patterns predicted new AF or mortality. Methods Within the Assessment of Pexelizumab in Acute Myocardial Infarction trial, a nested case-control study was conducted. Patients with new AF were matched 1:1 with controls, and baseline atrial electrocardiographic variables were examined. Results Abnormal P wave morphology (Liu minor criterion for atrial infarction) was significantly associated with new AF (adjusted odds ratio, 1.68; 1.03-2.73). This was also independently associated with 90-day mortality in the overall case-control cohort (adjusted hazard rate, 1.90; 1.04-3.46) and among patient with new-onset AF (adjusted hazard rate, 2.43; 1.22-4.84). Conclusions Abnormal P wave morphology significantly predicted new AF and 90-day mortality in STEMI patients.</description><identifier>ISSN: 0022-0736</identifier><identifier>EISSN: 1532-8430</identifier><identifier>DOI: 10.1016/j.jelectrocard.2010.04.001</identifier><identifier>PMID: 20444469</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal, Humanized ; Atrial fibrillation ; Atrial Fibrillation - diagnosis ; Atrial Fibrillation - mortality ; Atrial Fibrillation - prevention & control ; Atrial infarction ; Cardiovascular ; Comorbidity ; Electrocardiography - statistics & numerical data ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Myocardial infarction ; Myocardial Infarction - diagnosis ; Myocardial Infarction - drug therapy ; Myocardial Infarction - mortality ; Risk Assessment - methods ; Risk Factors ; Single-Chain Antibodies - administration & dosage ; Survival Analysis ; Survival Rate ; Treatment Outcome ; United States</subject><ispartof>Journal of electrocardiology, 2010-07, Vol.43 (4), p.351-358</ispartof><rights>Elsevier Inc.</rights><rights>2010 Elsevier Inc.</rights><rights>Copyright 2010 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-29dd8f40a37307416176777b940136480bd5b8cbc927b0722e5fe149d79c8d7b3</citedby><cites>FETCH-LOGICAL-c434t-29dd8f40a37307416176777b940136480bd5b8cbc927b0722e5fe149d79c8d7b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jelectrocard.2010.04.001$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20444469$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Diepen, Sean, MD</creatorcontrib><creatorcontrib>Siha, Hany, MD</creatorcontrib><creatorcontrib>Fu, Yuling, MD</creatorcontrib><creatorcontrib>Westerhout, Cynthia M., PhD</creatorcontrib><creatorcontrib>Lopes, Renato D., MD</creatorcontrib><creatorcontrib>Granger, Christopher B., MD</creatorcontrib><creatorcontrib>Armstrong, Paul W., MD</creatorcontrib><creatorcontrib>for the APEX AMI Investigators</creatorcontrib><creatorcontrib>APEX AMI Investigators</creatorcontrib><title>Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial</title><title>Journal of electrocardiology</title><addtitle>J Electrocardiol</addtitle><description>Abstract Background Atrial infarction reportedly occurs in 0.7% to 52% of ST-elevation myocardial infarctions (STEMIs), up to two thirds of whom develop atrial fibrillation and flutter (AF). Prospective validation of electrocardiographic atrial infarction patterns is lacking. Hence, in STEMI patients treated with primary percutaneous coronary intervention, we examined whether baseline atrial electrocardiographic changes or atrial infarction patterns predicted new AF or mortality. Methods Within the Assessment of Pexelizumab in Acute Myocardial Infarction trial, a nested case-control study was conducted. Patients with new AF were matched 1:1 with controls, and baseline atrial electrocardiographic variables were examined. Results Abnormal P wave morphology (Liu minor criterion for atrial infarction) was significantly associated with new AF (adjusted odds ratio, 1.68; 1.03-2.73). This was also independently associated with 90-day mortality in the overall case-control cohort (adjusted hazard rate, 1.90; 1.04-3.46) and among patient with new-onset AF (adjusted hazard rate, 2.43; 1.22-4.84). Conclusions Abnormal P wave morphology significantly predicted new AF and 90-day mortality in STEMI patients.</description><subject>Aged</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Atrial fibrillation</subject><subject>Atrial Fibrillation - diagnosis</subject><subject>Atrial Fibrillation - mortality</subject><subject>Atrial Fibrillation - prevention & control</subject><subject>Atrial infarction</subject><subject>Cardiovascular</subject><subject>Comorbidity</subject><subject>Electrocardiography - statistics & numerical data</subject><subject>Female</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myocardial infarction</subject><subject>Myocardial Infarction - diagnosis</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - mortality</subject><subject>Risk Assessment - methods</subject><subject>Risk Factors</subject><subject>Single-Chain Antibodies - administration & dosage</subject><subject>Survival Analysis</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>United States</subject><issn>0022-0736</issn><issn>1532-8430</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNks9u1DAQxiMEokvhFZDFhVOWceyNEw6gVcuflYpA6nK2HGfS9ZLYW9spLE_Lo-AlLVtxwpdI9je_mcz3ZdkLCnMKtHy1nW-xRx2908q38wLSA_A5AH2QzeiCFXnFGTzMZgBFkYNg5Un2JIQtANSFKB5nJwXwdMp6lv06d6RRAXtjkajojerJPbhxV17tNkYTZVtibKe8jsZZslMxoreB7Dy2Rkdi8XvubMB4R-lM403fqz9y1SU1uVzniX0zXQ37qUOSHrlvycoGc7WJgXTeDSRukCxDwBAGtJG4jnzBH2nYn-OgmlRHlnqMSD4dWavjjOvDHE-zR53qAz67_Z5mX9-_W599zC8-f1idLS9yzRmPeVG3bdVxUEwwEJyWVJRCiKbmQFnJK2jaRVPpRqcNNiCKAhcdUl63otZVKxp2mr2cuDvvrkcMUQ4maEwLsOjGIAVjdcXLSiTl60mpvQvBYyd33gzK7yUFeTBYbuV9g-XBYAlcJoNT8fPbNmMzYPu39M7RJDifBJh-9sagl0EbtDq55BNSts78X583_2B0iojRqv-GewxbN3qb1impDIUEeXmI2iFpNIWMVouK_QbSFdkZ</recordid><startdate>20100701</startdate><enddate>20100701</enddate><creator>van Diepen, Sean, MD</creator><creator>Siha, Hany, MD</creator><creator>Fu, Yuling, MD</creator><creator>Westerhout, Cynthia M., PhD</creator><creator>Lopes, Renato D., MD</creator><creator>Granger, Christopher B., MD</creator><creator>Armstrong, Paul W., MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100701</creationdate><title>Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial</title><author>van Diepen, Sean, MD ; Siha, Hany, MD ; Fu, Yuling, MD ; Westerhout, Cynthia M., PhD ; Lopes, Renato D., MD ; Granger, Christopher B., MD ; Armstrong, Paul W., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-29dd8f40a37307416176777b940136480bd5b8cbc927b0722e5fe149d79c8d7b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Atrial fibrillation</topic><topic>Atrial Fibrillation - diagnosis</topic><topic>Atrial Fibrillation - mortality</topic><topic>Atrial Fibrillation - prevention & control</topic><topic>Atrial infarction</topic><topic>Cardiovascular</topic><topic>Comorbidity</topic><topic>Electrocardiography - statistics & numerical data</topic><topic>Female</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myocardial infarction</topic><topic>Myocardial Infarction - diagnosis</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - mortality</topic><topic>Risk Assessment - methods</topic><topic>Risk Factors</topic><topic>Single-Chain Antibodies - administration & dosage</topic><topic>Survival Analysis</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Diepen, Sean, MD</creatorcontrib><creatorcontrib>Siha, Hany, MD</creatorcontrib><creatorcontrib>Fu, Yuling, MD</creatorcontrib><creatorcontrib>Westerhout, Cynthia M., PhD</creatorcontrib><creatorcontrib>Lopes, Renato D., MD</creatorcontrib><creatorcontrib>Granger, Christopher B., MD</creatorcontrib><creatorcontrib>Armstrong, Paul W., MD</creatorcontrib><creatorcontrib>for the APEX AMI Investigators</creatorcontrib><creatorcontrib>APEX AMI Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of electrocardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Diepen, Sean, MD</au><au>Siha, Hany, MD</au><au>Fu, Yuling, MD</au><au>Westerhout, Cynthia M., PhD</au><au>Lopes, Renato D., MD</au><au>Granger, Christopher B., MD</au><au>Armstrong, Paul W., MD</au><aucorp>for the APEX AMI Investigators</aucorp><aucorp>APEX AMI Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial</atitle><jtitle>Journal of electrocardiology</jtitle><addtitle>J Electrocardiol</addtitle><date>2010-07-01</date><risdate>2010</risdate><volume>43</volume><issue>4</issue><spage>351</spage><epage>358</epage><pages>351-358</pages><issn>0022-0736</issn><eissn>1532-8430</eissn><abstract>Abstract Background Atrial infarction reportedly occurs in 0.7% to 52% of ST-elevation myocardial infarctions (STEMIs), up to two thirds of whom develop atrial fibrillation and flutter (AF). Prospective validation of electrocardiographic atrial infarction patterns is lacking. Hence, in STEMI patients treated with primary percutaneous coronary intervention, we examined whether baseline atrial electrocardiographic changes or atrial infarction patterns predicted new AF or mortality. Methods Within the Assessment of Pexelizumab in Acute Myocardial Infarction trial, a nested case-control study was conducted. Patients with new AF were matched 1:1 with controls, and baseline atrial electrocardiographic variables were examined. Results Abnormal P wave morphology (Liu minor criterion for atrial infarction) was significantly associated with new AF (adjusted odds ratio, 1.68; 1.03-2.73). This was also independently associated with 90-day mortality in the overall case-control cohort (adjusted hazard rate, 1.90; 1.04-3.46) and among patient with new-onset AF (adjusted hazard rate, 2.43; 1.22-4.84). Conclusions Abnormal P wave morphology significantly predicted new AF and 90-day mortality in STEMI patients.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>20444469</pmid><doi>10.1016/j.jelectrocard.2010.04.001</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-0736 |
| ispartof | Journal of electrocardiology, 2010-07, Vol.43 (4), p.351-358 |
| issn | 0022-0736 1532-8430 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733984687 |
| source | MEDLINE; ScienceDirect |
| subjects | Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Atrial fibrillation Atrial Fibrillation - diagnosis Atrial Fibrillation - mortality Atrial Fibrillation - prevention & control Atrial infarction Cardiovascular Comorbidity Electrocardiography - statistics & numerical data Female Humans Incidence Male Middle Aged Myocardial infarction Myocardial Infarction - diagnosis Myocardial Infarction - drug therapy Myocardial Infarction - mortality Risk Assessment - methods Risk Factors Single-Chain Antibodies - administration & dosage Survival Analysis Survival Rate Treatment Outcome United States |
| title | Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T18%3A22%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Do%20baseline%20atrial%20electrocardiographic%20and%20infarction%20patterns%20predict%20new-onset%20atrial%20fibrillation%20after%20ST-elevation%20myocardial%20infarction?%20Insights%20from%20the%20Assessment%20of%20Pexelizumab%20in%20Acute%20Myocardial%20Infarction%20Trial&rft.jtitle=Journal%20of%20electrocardiology&rft.au=van%20Diepen,%20Sean,%20MD&rft.aucorp=for%20the%20APEX%20AMI%20Investigators&rft.date=2010-07-01&rft.volume=43&rft.issue=4&rft.spage=351&rft.epage=358&rft.pages=351-358&rft.issn=0022-0736&rft.eissn=1532-8430&rft_id=info:doi/10.1016/j.jelectrocard.2010.04.001&rft_dat=%3Cproquest_cross%3E733984687%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733984687&rft_id=info:pmid/20444469&rft_els_id=1_s2_0_S0022073610001858&rfr_iscdi=true |